Corvus Pharmaceuticals Soars to Eight-Year High on Promising Eczema Treatment Results

Biotech stock Corvus Pharmaceuticals (NASDAQ: CRVS) climbed to an eight-year high on Tuesday, fueled by encouraging results from its eczema treatment study. The company’s experimental pill, soquelitinib, demonstrated significant improvements in patients over an eight-week trial, marking a major milestone in the treatment of moderate to severe eczema.

Breakthrough Results in Eczema Treatment

The recent study tested twice-daily doses of soquelitinib over an extended eight-week period. Notably, patients exhibited steeper responses compared to a previous four-week study, according to Oppenheimer analyst Jeff Jones. In his report, Jones highlighted that the treatment was effective across a broad range of patients, regardless of whether they had undergone prior systemic therapy. Moreover, the study revealed changes across multiple inflammatory biomarkers, further underscoring the drug’s potential.

Impressive Market Reaction

As a result of these findings, Corvus shares surged more than 90% in morning trading, reaching $15.63. This marked the stock’s highest opening price since June 2018, reflecting investor confidence in the company’s progress.

Key Metrics: Eczema Severity and Symptom Reduction

One of the most critical measures for evaluating eczema treatments is the Eczema Area and Severity Index (EASI), which assesses the extent and severity of the condition. In Corvus’ eight-week study, an impressive 75% of patients achieved a 75% reduction in eczema symptoms based on their EASI scores. Additionally, 25% of participants reached 90% eczema clearance, while one-third of patients achieved clear or nearly clear skin on the Investigator’s Global Assessment (IGA) scale.

What’s Next for Soquelitinib?

Encouraged by these results, Corvus Pharmaceuticals is preparing to launch a Phase 2 study later this quarter. This next phase will focus on patients with moderate to severe eczema who have not responded to at least one prior topical or systemic treatment. According to Chief Executive Richard Miller, the extended treatment period in the Phase 1 study not only strengthened the results but also maintained a strong safety profile.

“Bottom line, we believe this is a successful Phase 1 program, and the results have become stronger the longer we treat, without compromising safety,” Miller said in a written statement. “We believe this bodes well for advancing soquelitinib to the next phase, where we will further test soquelitinib in a larger patient population.”

A Promising Future for Eczema Treatment

The promising results suggest that soquelitinib could emerge as a leading oral treatment for eczema, offering hope to patients who have struggled with limited options. With the Phase 2 study on the horizon, Corvus Pharmaceuticals is poised to further solidify its position in the biotech space.

As the company continues to advance its research, investors and patients alike will be watching closely to see if soquelitinib can deliver on its potential to transform eczema treatment.

For more information on Corvus Pharmaceuticals please visit www.corvuspharma.com.